424 related articles for article (PubMed ID: 28128058)
21. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
[TBL] [Abstract][Full Text] [Related]
22. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
[TBL] [Abstract][Full Text] [Related]
23. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.
Vinci P; Di Girolamo FG; Panizon E; Tosoni LM; Cerrato C; Pellicori F; Altamura N; Pirulli A; Zaccari M; Biasinutto C; Roni C; Fiotti N; Schincariol P; Mangogna A; Biolo G
Int J Environ Res Public Health; 2023 Sep; 20(18):. PubMed ID: 37754581
[TBL] [Abstract][Full Text] [Related]
24. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.
Scipione CA; Koschinsky ML; Boffa MB
Crit Rev Clin Lab Sci; 2018 Jan; 55(1):33-54. PubMed ID: 29262744
[TBL] [Abstract][Full Text] [Related]
25. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
[TBL] [Abstract][Full Text] [Related]
26. [Lipoprotein(a) as a cardiovascular risk factor].
van Lennep JE; Mulder MT
Ned Tijdschr Geneeskd; 2011; 155(42):A3582. PubMed ID: 22027461
[TBL] [Abstract][Full Text] [Related]
27. Lipoprotein(a) as a cardiovascular risk factor: current status.
Nordestgaard BG; Chapman MJ; Ray K; Borén J; Andreotti F; Watts GF; Ginsberg H; Amarenco P; Catapano A; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A;
Eur Heart J; 2010 Dec; 31(23):2844-53. PubMed ID: 20965889
[TBL] [Abstract][Full Text] [Related]
28. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
Fras Z
Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
[TBL] [Abstract][Full Text] [Related]
29. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.
Graham MJ; Viney N; Crooke RM; Tsimikas S
J Lipid Res; 2016 Mar; 57(3):340-51. PubMed ID: 26538546
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein.
Saeed A; Virani SS
Front Biosci (Landmark Ed); 2018 Jan; 23(6):1099-1112. PubMed ID: 28930591
[TBL] [Abstract][Full Text] [Related]
31. Lipoprotein(a): the revenant.
Gencer B; Kronenberg F; Stroes ES; Mach F
Eur Heart J; 2017 May; 38(20):1553-1560. PubMed ID: 28329241
[TBL] [Abstract][Full Text] [Related]
32. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
33. Lipoprotein(a).
Kronenberg F
Handb Exp Pharmacol; 2022; 270():201-232. PubMed ID: 34196811
[TBL] [Abstract][Full Text] [Related]
34. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
[TBL] [Abstract][Full Text] [Related]
35. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.
Boffa MB; Marar TT; Yeang C; Viney NJ; Xia S; Witztum JL; Koschinsky ML; Tsimikas S
J Lipid Res; 2019 Dec; 60(12):2082-2089. PubMed ID: 31551368
[TBL] [Abstract][Full Text] [Related]
36. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
37. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
[TBL] [Abstract][Full Text] [Related]
38. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
[TBL] [Abstract][Full Text] [Related]
39. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
40. Lipoprotein(a): more interesting than ever after 50 years.
Dubé JB; Boffa MB; Hegele RA; Koschinsky ML
Curr Opin Lipidol; 2012 Apr; 23(2):133-40. PubMed ID: 22327610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
